Trial Profile
A phase 2 study of Relacorilant to treat patients with antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis ("NASH")
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 11 May 2020
Price :
$35
*
At a glance
- Drugs Relacorilant (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 04 May 2020 According to a Corcept Therapeutics media release, this trial have been delayed one quarter.
- 26 Feb 2018 New trial record
- 22 Feb 2018 According to a Corcept Therapeutics media release, company is planning to initiate this study by year end 2018.